Advanced CRC
Standard of care in CRC requires testing for BRAF, ERBB2 (HER2), KRAS, MSI, NRAS, and NTRK.
Download Study
Pre-treatment imaging
Post-treatment imaging
*Representative patient images
Patient Case
Clinical presentation
- 63-year-old male referred to a large cancer center after metastases appeared
Testing
- No previous genomic testing
- Oncologist ordered Guardant360® LDT to receive guideline-recommended results within 7 days while locating archival tissue sample
- Guardant360 found a KRAS exon 4 mutation
Treatment
- Oncologist excluded anti-EGFR therapy from the patient’s treatment plan
- The patient was put on FOLFOX + anti-VEGF therapy and has had a strong response for more than 6 months
